T-109 P.02

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

	(Case N	o. 00-1213)		
In re	Application of: Saris et al.	PATENT		
Seria	l No.: 09/724,583	) Before the Examiner: P. Mertz		
Filed	: November 28, 2000	) Group Art Unit: 1646		
For:	Interleukin-1 Receptor Antagonist-Related Molecules and Uses Thereof	) ) )		
	nissioner for Patents ington, D.C. 20231			
Sir:				
TRANSMITTAL LETTER				
1.	We are transmitting herewith the attached papers for the above-described patent application: <u>Petition for Three-Month Extension of Time, Response to Office Action, and return postcard</u>			
2.	GENERAL AUTHORIZATION TO CHARGE OR CREDIT FEES: Please charge any additional fees to Deposit Account No. 13-2490.			
3.	The undersigned hereby certifies that this Transmittal Letter and this paper, as described in paragraph 1 herein above, are being facsimile transmitted to the Patent and Trademark Office (Fax No. 703-308-4227) on January 2, 2003.			
Dated:	January 2, 2003	Respectfully submitted,  McDennell Boehnen Hulbert & Berghoff  By:  Donald L. Zuhn, Ph.D.  Reg. No. 48,710		



McDonnell Boehnen Hulbert & Berghoff Law Offices

**FAX RECEIVED** JAN 0 3 2003 GROUP 1600

### Fax transmittal

To

Prema Maria Mertz

Company

U.S. Patent & Trademark Office

Fax

703-308-4227

Phone

703-308-4229

Pages,

38

with cover

U.S. Application No. 09/724,583

Date From

312-913-2132 Direct

zuhn@mbhb.com Email

349-45 C/M

T-109 P.03 Job-118

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (Case No. 00-1213)

(Case	e 1 <b>40.</b> UU	1213)	PATENT
in re Application of: Saris et al.	)		IAIBNI
Serial No.: 09/724,583	)	Before the Examiner:	P. Mertz
Filed: November 28, 2000	)	Group Art Unit: 1646	
For: Interleukin-1 Receptor Antagonist-Related Molecules and Uses Thereof	)		
Commissioner for Patents Washington, D.C. 20231			

Sir:

#### RESPONSE TO OFFICE ACTION MAILED JULY 2, 2002

Responsive to the Office Action mailed July 2, 2002, Applicants respectfully request reconsideration of the above-identified application in view of the following amendments and remarks.

#### **AMENDMENTS**

The Examiner is respectfully requested to enter the following amendments.

#### In the Specification:

Please amend the title at page 2, lines 1-2 to read as follows:



### NUCLEIC ACIDS ENCODING INTERLEUKIN-1 RECEPTOR ANTAGONIST-RELATED-PROTEINS AND USES THEREOF

#### In the Claims:

Please amend the following claims:

12

- 1. (Amended) An isolated nucleic acid molecule comprising a nucleotide sequence:
- (a) as set forth in SEQ ID NO: 1;
- (b) of the DNA insert in ATCC Deposit No. PTA-1423;